Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8261 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8214 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8214 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8074 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7985 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7947 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7941 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7929 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7857 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7826 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7786 |
Intermediate Similarity |
NPD228 |
Approved |
0.7692 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7692 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7651 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.761 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7606 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7586 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7566 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7561 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7516 |
Intermediate Similarity |
NPD37 |
Approved |
0.7515 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7515 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.75 |
Intermediate Similarity |
NPD7228 |
Approved |
0.75 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7484 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7484 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7484 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7447 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7407 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7407 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7381 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7333 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7321 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7303 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7303 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7299 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7296 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7293 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7285 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7278 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7273 |
Intermediate Similarity |
NPD968 |
Approved |
0.7267 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.723 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7222 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7212 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7203 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7203 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD3060 |
Approved |
0.719 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7183 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7162 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.716 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.716 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7133 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7123 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7118 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7111 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7111 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7107 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD6190 |
Approved |
0.709 |
Intermediate Similarity |
NPD290 |
Approved |
0.7086 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7086 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7078 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7075 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.707 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7067 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7066 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7066 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7066 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7044 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7042 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7042 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7039 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7037 |
Intermediate Similarity |
NPD5773 |
Approved |
0.7037 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7037 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7032 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7032 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7021 |
Intermediate Similarity |
NPD1182 |
Approved |
0.7018 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7014 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7014 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD1511 |
Approved |
0.6987 |
Remote Similarity |
NPD2677 |
Approved |
0.6981 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.697 |
Remote Similarity |
NPD291 |
Approved |
0.6959 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6954 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD5735 |
Approved |
0.695 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6948 |
Remote Similarity |
NPD5762 |
Approved |
0.6948 |
Remote Similarity |
NPD5763 |
Approved |
0.6948 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.6929 |
Remote Similarity |
NPD6671 |
Approved |
0.6923 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6923 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD5126 |
Approved |
0.6918 |
Remote Similarity |
NPD8651 |
Approved |
0.6918 |
Remote Similarity |
NPD1512 |
Approved |
0.6913 |
Remote Similarity |
NPD7095 |
Approved |
0.6909 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6909 |
Remote Similarity |
NPD5604 |
Discontinued |
0.6908 |
Remote Similarity |
NPD6653 |
Approved |
0.6897 |
Remote Similarity |
NPD1840 |
Phase 2 |
0.689 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6863 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6861 |
Remote Similarity |
NPD556 |
Approved |
0.6852 |
Remote Similarity |
NPD4675 |
Approved |
0.6852 |
Remote Similarity |
NPD4678 |
Approved |
0.6849 |
Remote Similarity |
NPD3685 |
Discontinued |
0.6842 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD3657 |
Discovery |
0.6839 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6828 |
Remote Similarity |
NPD1535 |
Discovery |
0.6821 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6815 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6813 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6806 |
Remote Similarity |
NPD9381 |
Approved |
0.6806 |
Remote Similarity |
NPD9384 |
Approved |
0.6792 |
Remote Similarity |
NPD1774 |
Approved |
0.6788 |
Remote Similarity |
NPD2563 |
Approved |
0.6788 |
Remote Similarity |
NPD2560 |
Approved |
0.6786 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6783 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6781 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.6781 |
Remote Similarity |
NPD1608 |
Approved |
0.6779 |
Remote Similarity |
NPD9494 |
Approved |
0.6776 |
Remote Similarity |
NPD4140 |
Approved |
0.6776 |
Remote Similarity |
NPD3059 |
Approved |
0.6776 |
Remote Similarity |
NPD3061 |
Approved |
0.6776 |
Remote Similarity |
NPD3062 |
Approved |
0.6774 |
Remote Similarity |
NPD3539 |
Phase 1 |
0.6774 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.6765 |
Remote Similarity |
NPD2489 |
Approved |
0.6765 |
Remote Similarity |
NPD27 |
Approved |
0.6763 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6759 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6757 |
Remote Similarity |
NPD7680 |
Approved |
0.6755 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6752 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.675 |
Remote Similarity |
NPD3536 |
Discontinued |
0.6746 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6735 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6735 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6735 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6727 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6721 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6714 |
Remote Similarity |
NPD5535 |
Approved |
0.6712 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6711 |
Remote Similarity |
NPD558 |
Phase 2 |
0.6711 |
Remote Similarity |
NPD554 |
Clinical (unspecified phase) |
0.671 |
Remote Similarity |
NPD4108 |
Discontinued |
0.671 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6709 |
Remote Similarity |
NPD4535 |
Phase 3 |
0.6706 |
Remote Similarity |
NPD2970 |
Approved |
0.6706 |
Remote Similarity |
NPD2969 |
Approved |
0.6705 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.669 |
Remote Similarity |
NPD2107 |
Clinical (unspecified phase) |
0.6689 |
Remote Similarity |
NPD3180 |
Approved |
0.6689 |
Remote Similarity |
NPD3179 |
Approved |
0.6689 |
Remote Similarity |
NPD6696 |
Suspended |
0.6689 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6688 |
Remote Similarity |
NPD3054 |
Approved |
0.6688 |
Remote Similarity |
NPD5314 |
Approved |
0.6688 |
Remote Similarity |
NPD3052 |
Approved |
0.6686 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6685 |
Remote Similarity |
NPD6842 |
Approved |
0.6685 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6685 |
Remote Similarity |
NPD6841 |
Approved |
0.6667 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD2122 |
Discontinued |
0.6667 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD7007 |
Discovery |
0.6667 |
Remote Similarity |
NPD6032 |
Approved |
0.6667 |
Remote Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD5241 |
Discontinued |
0.6648 |
Remote Similarity |
NPD8313 |
Approved |
0.6648
|
Remote Similarity |
NPD8312 |
Approved |